Key facts
- It has raised $102.0M; the latest was Early Stage VC ($100.0M) in Sep 2024.
- Notable investors include Shenzhen Capital Group, GL Ventures, Tailong VC, HBM Partners, Guanghua Kaiyuan Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for C-Ray Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for C-Ray Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About C-Ray Therapeutics
Developer and manufacturer of radiopharmaceuticals designed to treat tumors. The company's radiopharmaceutical is a radionuclide preparation or a compound or biological agent labeled with a radionuclide, enabling users to diagnose or treatment of diseases.
- Sector
- Healthcare
- HQ
- Hong Kong, Hong Kong
- Founded
- 2020
- Website
- c-raytherapeutics.com/
- Ownership
- Privately Held (backing)
C-Ray Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in C-Ray Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on C-Ray Therapeutics in its N-PORT filings yet. We sweep new filings monthly.